A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder Article Swipe
Kelesitse Phiri
,
Jesper Hallas
,
Marie Linder
,
Andrea V. Margulis
,
Brandon T. Suehs
,
Alejandro Arana
,
Shahram Bahmanyar
,
Veena Hoffman
,
Cheryl Enger
,
Libby Horter
,
Ingvild Odsbu
,
Morten Olesen
,
Susana Perez‐Gutthann
,
Nina Sahlertz Kristiansen
,
Kwame Appenteng
,
Stefan de Vogel
,
John D. Seeger
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1080/03007995.2021.1891035
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1080/03007995.2021.1891035
The results suggest no association between mirabegron use and risk of cancer, compared with antimuscarinic medications, in either men or women. Registration: EU PAS Register Number: EUPAS16088.
Related Topics
Concepts
Medicine
Mirabegron
Overactive bladder
Urology
Bladder cancer
Urothelial cancer
Internal medicine
Cancer
Oncology
Alternative medicine
Pathology
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1080/03007995.2021.1891035
- https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1891035?needAccess=true
- OA Status
- hybrid
- Cited By
- 5
- References
- 24
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3132316162
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3132316162Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1080/03007995.2021.1891035Digital Object Identifier
- Title
-
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladderWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-02-19Full publication date if available
- Authors
-
Kelesitse Phiri, Jesper Hallas, Marie Linder, Andrea V. Margulis, Brandon T. Suehs, Alejandro Arana, Shahram Bahmanyar, Veena Hoffman, Cheryl Enger, Libby Horter, Ingvild Odsbu, Morten Olesen, Susana Perez‐Gutthann, Nina Sahlertz Kristiansen, Kwame Appenteng, Stefan de Vogel, John D. SeegerList of authors in order
- Landing page
-
https://doi.org/10.1080/03007995.2021.1891035Publisher landing page
- PDF URL
-
https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1891035?needAccess=trueDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1891035?needAccess=trueDirect OA link when available
- Concepts
-
Medicine, Mirabegron, Overactive bladder, Urology, Bladder cancer, Urothelial cancer, Internal medicine, Cancer, Oncology, Alternative medicine, PathologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 1, 2023: 1, 2022: 2Per-year citation counts (last 5 years)
- References (count)
-
24Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3132316162 |
|---|---|
| doi | https://doi.org/10.1080/03007995.2021.1891035 |
| ids.doi | https://doi.org/10.1080/03007995.2021.1891035 |
| ids.mag | 3132316162 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33591859 |
| ids.openalex | https://openalex.org/W3132316162 |
| fwci | 1.11895107 |
| mesh[0].qualifier_ui | Q000009 |
| mesh[0].descriptor_ui | D000083 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | adverse effects |
| mesh[0].descriptor_name | Acetanilides |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D005260 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Female |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D006801 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Humans |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008297 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Male |
| mesh[4].qualifier_ui | Q000009 |
| mesh[4].descriptor_ui | D018727 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | adverse effects |
| mesh[4].descriptor_name | Muscarinic Antagonists |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D009369 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Neoplasms |
| mesh[6].qualifier_ui | Q000453 |
| mesh[6].descriptor_ui | D009369 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | epidemiology |
| mesh[6].descriptor_name | Neoplasms |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D013844 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Thiazoles |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D016896 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Treatment Outcome |
| mesh[9].qualifier_ui | Q000188 |
| mesh[9].descriptor_ui | D053201 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | drug therapy |
| mesh[9].descriptor_name | Urinary Bladder, Overactive |
| mesh[10].qualifier_ui | Q000453 |
| mesh[10].descriptor_ui | D053201 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | epidemiology |
| mesh[10].descriptor_name | Urinary Bladder, Overactive |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D064804 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Urological Agents |
| mesh[12].qualifier_ui | Q000009 |
| mesh[12].descriptor_ui | D000083 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | adverse effects |
| mesh[12].descriptor_name | Acetanilides |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D005260 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Female |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D006801 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Humans |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D008297 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Male |
| mesh[16].qualifier_ui | Q000009 |
| mesh[16].descriptor_ui | D018727 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | adverse effects |
| mesh[16].descriptor_name | Muscarinic Antagonists |
| mesh[17].qualifier_ui | Q000188 |
| mesh[17].descriptor_ui | D009369 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | drug therapy |
| mesh[17].descriptor_name | Neoplasms |
| mesh[18].qualifier_ui | Q000453 |
| mesh[18].descriptor_ui | D009369 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | epidemiology |
| mesh[18].descriptor_name | Neoplasms |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D013844 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Thiazoles |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D016896 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Treatment Outcome |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D053201 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Urinary Bladder, Overactive |
| mesh[22].qualifier_ui | Q000453 |
| mesh[22].descriptor_ui | D053201 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | epidemiology |
| mesh[22].descriptor_name | Urinary Bladder, Overactive |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D064804 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Urological Agents |
| type | article |
| title | A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder |
| biblio.issue | 5 |
| biblio.volume | 37 |
| biblio.last_page | 877 |
| biblio.first_page | 867 |
| topics[0].id | https://openalex.org/T10279 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2748 |
| topics[0].subfield.display_name | Urology |
| topics[0].display_name | Urinary Bladder and Prostate Research |
| topics[1].id | https://openalex.org/T10418 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9983999729156494 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2745 |
| topics[1].subfield.display_name | Rheumatology |
| topics[1].display_name | Pelvic floor disorders treatments |
| topics[2].id | https://openalex.org/T10458 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.995199978351593 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Bladder and Urothelial Cancer Treatments |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9728773832321167 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778164427 |
| concepts[1].level | 4 |
| concepts[1].score | 0.9480443000793457 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q3702534 |
| concepts[1].display_name | Mirabegron |
| concepts[2].id | https://openalex.org/C2778941218 |
| concepts[2].level | 3 |
| concepts[2].score | 0.9034225940704346 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q331231 |
| concepts[2].display_name | Overactive bladder |
| concepts[3].id | https://openalex.org/C126894567 |
| concepts[3].level | 1 |
| concepts[3].score | 0.7030927538871765 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q105650 |
| concepts[3].display_name | Urology |
| concepts[4].id | https://openalex.org/C2780352672 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6389976143836975 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q504775 |
| concepts[4].display_name | Bladder cancer |
| concepts[5].id | https://openalex.org/C3020745361 |
| concepts[5].level | 4 |
| concepts[5].score | 0.6077117919921875 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2501186 |
| concepts[5].display_name | Urothelial cancer |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.3539614677429199 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C121608353 |
| concepts[7].level | 2 |
| concepts[7].score | 0.33771997690200806 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[7].display_name | Cancer |
| concepts[8].id | https://openalex.org/C143998085 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3328063488006592 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[8].display_name | Oncology |
| concepts[9].id | https://openalex.org/C204787440 |
| concepts[9].level | 2 |
| concepts[9].score | 0.0942976176738739 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[9].display_name | Alternative medicine |
| concepts[10].id | https://openalex.org/C142724271 |
| concepts[10].level | 1 |
| concepts[10].score | 0.06211543083190918 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[10].display_name | Pathology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9728773832321167 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/mirabegron |
| keywords[1].score | 0.9480443000793457 |
| keywords[1].display_name | Mirabegron |
| keywords[2].id | https://openalex.org/keywords/overactive-bladder |
| keywords[2].score | 0.9034225940704346 |
| keywords[2].display_name | Overactive bladder |
| keywords[3].id | https://openalex.org/keywords/urology |
| keywords[3].score | 0.7030927538871765 |
| keywords[3].display_name | Urology |
| keywords[4].id | https://openalex.org/keywords/bladder-cancer |
| keywords[4].score | 0.6389976143836975 |
| keywords[4].display_name | Bladder cancer |
| keywords[5].id | https://openalex.org/keywords/urothelial-cancer |
| keywords[5].score | 0.6077117919921875 |
| keywords[5].display_name | Urothelial cancer |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.3539614677429199 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/cancer |
| keywords[7].score | 0.33771997690200806 |
| keywords[7].display_name | Cancer |
| keywords[8].id | https://openalex.org/keywords/oncology |
| keywords[8].score | 0.3328063488006592 |
| keywords[8].display_name | Oncology |
| keywords[9].id | https://openalex.org/keywords/alternative-medicine |
| keywords[9].score | 0.0942976176738739 |
| keywords[9].display_name | Alternative medicine |
| keywords[10].id | https://openalex.org/keywords/pathology |
| keywords[10].score | 0.06211543083190918 |
| keywords[10].display_name | Pathology |
| language | en |
| locations[0].id | doi:10.1080/03007995.2021.1891035 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S206643269 |
| locations[0].source.issn | 0300-7995, 1473-4877 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0300-7995 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Current Medical Research and Opinion |
| locations[0].source.host_organization | https://openalex.org/P4310320547 |
| locations[0].source.host_organization_name | Taylor & Francis |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320547 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1891035?needAccess=true |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Current Medical Research and Opinion |
| locations[0].landing_page_url | https://doi.org/10.1080/03007995.2021.1891035 |
| locations[1].id | pmid:33591859 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Current medical research and opinion |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33591859 |
| locations[2].id | pmh:oai:sdu.dk:publications/cae038e8-280e-415e-9dca-38d7f683c98c |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400423 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | University of Southern Denmark Research Portal (University of Southern Denmark) |
| locations[2].source.host_organization | https://openalex.org/I177969490 |
| locations[2].source.host_organization_name | University of Southern Denmark |
| locations[2].source.host_organization_lineage | https://openalex.org/I177969490 |
| locations[2].license | cc-by-nc-nd |
| locations[2].pdf_url | https://findresearcher.sdu.dk:8443/ws/files/182731230/Phiri_2021_A_study_of_cancer_occurrence_in_use.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | |
| locations[2].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Phiri , K , Hallas , J , Linder , M , Margulis , A , Suehs , B , Arana , A , Bahmanyar , S , Hoffman , V , Enger , C , Horter , L , Odsbu , I , Olesen , M , Perez-Gutthann , S , Kristiansen , N S , Appenteng , K , de Vogel , S & Seeger , J 2021 , ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ' , Current Medical Research and Opinion , vol. 37 , no. 5 , pp. 867-877 . https://doi.org/10.1080/03007995.2021.1891035 |
| locations[2].landing_page_url | https://portal.findresearcher.sdu.dk/da/publications/cae038e8-280e-415e-9dca-38d7f683c98c |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5046034263 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-6847-0231 |
| authorships[0].author.display_name | Kelesitse Phiri |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I25026578, https://openalex.org/I4210124242 |
| authorships[0].affiliations[0].raw_affiliation_string | Optum Epidemiology, Boston, MA, USA |
| authorships[0].institutions[0].id | https://openalex.org/I25026578 |
| authorships[0].institutions[0].ror | https://ror.org/02t110213 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I25026578 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | New England College of Optometry |
| authorships[0].institutions[1].id | https://openalex.org/I4210124242 |
| authorships[0].institutions[1].ror | https://ror.org/0370sjj75 |
| authorships[0].institutions[1].type | company |
| authorships[0].institutions[1].lineage | https://openalex.org/I4210124242 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | Optum (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Kelesitse Phiri |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Optum Epidemiology, Boston, MA, USA |
| authorships[1].author.id | https://openalex.org/A5086275374 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-8097-8708 |
| authorships[1].author.display_name | Jesper Hallas |
| authorships[1].countries | DK |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I177969490 |
| authorships[1].affiliations[0].raw_affiliation_string | Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark |
| authorships[1].institutions[0].id | https://openalex.org/I177969490 |
| authorships[1].institutions[0].ror | https://ror.org/03yrrjy16 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I177969490 |
| authorships[1].institutions[0].country_code | DK |
| authorships[1].institutions[0].display_name | University of Southern Denmark |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Jesper Hallas |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark |
| authorships[2].author.id | https://openalex.org/A5007122786 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-2619-2189 |
| authorships[2].author.display_name | Marie Linder |
| authorships[2].countries | SE |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I28166907 |
| authorships[2].affiliations[0].raw_affiliation_string | Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden |
| authorships[2].institutions[0].id | https://openalex.org/I28166907 |
| authorships[2].institutions[0].ror | https://ror.org/056d84691 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I28166907 |
| authorships[2].institutions[0].country_code | SE |
| authorships[2].institutions[0].display_name | Karolinska Institutet |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Marie Linder |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden |
| authorships[3].author.id | https://openalex.org/A5002700523 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-7388-6082 |
| authorships[3].author.display_name | Andrea V. Margulis |
| authorships[3].affiliations[0].raw_affiliation_string | Epidemiology, RTI Health Solutions, Barcelona, Spain |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Andrea Margulis |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Epidemiology, RTI Health Solutions, Barcelona, Spain |
| authorships[4].author.id | https://openalex.org/A5031146373 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-4708-7484 |
| authorships[4].author.display_name | Brandon T. Suehs |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I96048030 |
| authorships[4].affiliations[0].raw_affiliation_string | Humana Healthcare Research, Humana, Louisville, KY, USA |
| authorships[4].institutions[0].id | https://openalex.org/I96048030 |
| authorships[4].institutions[0].ror | https://ror.org/04gxnqr83 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I96048030 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Humana (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Brandon Suehs |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Humana Healthcare Research, Humana, Louisville, KY, USA |
| authorships[5].author.id | https://openalex.org/A5086526085 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-1593-3124 |
| authorships[5].author.display_name | Alejandro Arana |
| authorships[5].affiliations[0].raw_affiliation_string | Epidemiology, RTI Health Solutions, Barcelona, Spain |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Alejandro Arana |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Epidemiology, RTI Health Solutions, Barcelona, Spain |
| authorships[6].author.id | https://openalex.org/A5022338649 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-9205-6540 |
| authorships[6].author.display_name | Shahram Bahmanyar |
| authorships[6].countries | SE |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I28166907 |
| authorships[6].affiliations[0].raw_affiliation_string | Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden |
| authorships[6].institutions[0].id | https://openalex.org/I28166907 |
| authorships[6].institutions[0].ror | https://ror.org/056d84691 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I28166907 |
| authorships[6].institutions[0].country_code | SE |
| authorships[6].institutions[0].display_name | Karolinska Institutet |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Shahram Bahmanyar |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden |
| authorships[7].author.id | https://openalex.org/A5082099394 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-4932-0892 |
| authorships[7].author.display_name | Veena Hoffman |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I25026578, https://openalex.org/I4210124242 |
| authorships[7].affiliations[0].raw_affiliation_string | Optum Epidemiology, Boston, MA, USA |
| authorships[7].institutions[0].id | https://openalex.org/I25026578 |
| authorships[7].institutions[0].ror | https://ror.org/02t110213 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I25026578 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | New England College of Optometry |
| authorships[7].institutions[1].id | https://openalex.org/I4210124242 |
| authorships[7].institutions[1].ror | https://ror.org/0370sjj75 |
| authorships[7].institutions[1].type | company |
| authorships[7].institutions[1].lineage | https://openalex.org/I4210124242 |
| authorships[7].institutions[1].country_code | US |
| authorships[7].institutions[1].display_name | Optum (United States) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Veena Hoffman |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Optum Epidemiology, Boston, MA, USA |
| authorships[8].author.id | https://openalex.org/A5029506986 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-1007-851X |
| authorships[8].author.display_name | Cheryl Enger |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I25026578, https://openalex.org/I4210124242 |
| authorships[8].affiliations[0].raw_affiliation_string | Optum Epidemiology, Boston, MA, USA |
| authorships[8].institutions[0].id | https://openalex.org/I25026578 |
| authorships[8].institutions[0].ror | https://ror.org/02t110213 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I25026578 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | New England College of Optometry |
| authorships[8].institutions[1].id | https://openalex.org/I4210124242 |
| authorships[8].institutions[1].ror | https://ror.org/0370sjj75 |
| authorships[8].institutions[1].type | company |
| authorships[8].institutions[1].lineage | https://openalex.org/I4210124242 |
| authorships[8].institutions[1].country_code | US |
| authorships[8].institutions[1].display_name | Optum (United States) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Cheryl Enger |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Optum Epidemiology, Boston, MA, USA |
| authorships[9].author.id | https://openalex.org/A5064412665 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-2503-1690 |
| authorships[9].author.display_name | Libby Horter |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I96048030 |
| authorships[9].affiliations[0].raw_affiliation_string | Humana Healthcare Research, Humana, Louisville, KY, USA |
| authorships[9].institutions[0].id | https://openalex.org/I96048030 |
| authorships[9].institutions[0].ror | https://ror.org/04gxnqr83 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I96048030 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Humana (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Libby Horter |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Humana Healthcare Research, Humana, Louisville, KY, USA |
| authorships[10].author.id | https://openalex.org/A5045904952 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-5337-8619 |
| authorships[10].author.display_name | Ingvild Odsbu |
| authorships[10].countries | SE |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I28166907 |
| authorships[10].affiliations[0].raw_affiliation_string | Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden |
| authorships[10].institutions[0].id | https://openalex.org/I28166907 |
| authorships[10].institutions[0].ror | https://ror.org/056d84691 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I28166907 |
| authorships[10].institutions[0].country_code | SE |
| authorships[10].institutions[0].display_name | Karolinska Institutet |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Ingvild Odsbu |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Centre for Pharmacoepidemiology, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden |
| authorships[11].author.id | https://openalex.org/A5001078445 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-0937-4952 |
| authorships[11].author.display_name | Morten Olesen |
| authorships[11].countries | DK |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I177969490 |
| authorships[11].affiliations[0].raw_affiliation_string | Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark |
| authorships[11].institutions[0].id | https://openalex.org/I177969490 |
| authorships[11].institutions[0].ror | https://ror.org/03yrrjy16 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I177969490 |
| authorships[11].institutions[0].country_code | DK |
| authorships[11].institutions[0].display_name | University of Southern Denmark |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Morten Olesen |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark |
| authorships[12].author.id | https://openalex.org/A5025500200 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-5798-3691 |
| authorships[12].author.display_name | Susana Perez‐Gutthann |
| authorships[12].affiliations[0].raw_affiliation_string | Epidemiology, RTI Health Solutions, Barcelona, Spain |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Susana Perez-Gutthann |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Epidemiology, RTI Health Solutions, Barcelona, Spain |
| authorships[13].author.id | https://openalex.org/A5008471016 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-2252-1475 |
| authorships[13].author.display_name | Nina Sahlertz Kristiansen |
| authorships[13].countries | DK |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I177969490 |
| authorships[13].affiliations[0].raw_affiliation_string | Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark |
| authorships[13].institutions[0].id | https://openalex.org/I177969490 |
| authorships[13].institutions[0].ror | https://ror.org/03yrrjy16 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I177969490 |
| authorships[13].institutions[0].country_code | DK |
| authorships[13].institutions[0].display_name | University of Southern Denmark |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Nina Sahlertz Kristiansen |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark |
| authorships[14].author.id | https://openalex.org/A5009610967 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Kwame Appenteng |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210165171 |
| authorships[14].affiliations[0].raw_affiliation_string | Pharmacovigilance, Astellas Pharma US, Chicago, IL, USA |
| authorships[14].institutions[0].id | https://openalex.org/I4210165171 |
| authorships[14].institutions[0].ror | https://ror.org/05pw69n24 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I142395110, https://openalex.org/I4210165171 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Astellas Pharma (United States) |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Kwame Appenteng |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Pharmacovigilance, Astellas Pharma US, Chicago, IL, USA |
| authorships[15].author.id | https://openalex.org/A5103125689 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-7318-2288 |
| authorships[15].author.display_name | Stefan de Vogel |
| authorships[15].countries | NL |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210157866 |
| authorships[15].affiliations[0].raw_affiliation_string | Pharmacovigilance, Astellas Pharma Europe B.V, Leiden, The Netherlands |
| authorships[15].institutions[0].id | https://openalex.org/I4210157866 |
| authorships[15].institutions[0].ror | https://ror.org/04kyfd050 |
| authorships[15].institutions[0].type | company |
| authorships[15].institutions[0].lineage | https://openalex.org/I142395110, https://openalex.org/I4210157866 |
| authorships[15].institutions[0].country_code | NL |
| authorships[15].institutions[0].display_name | Astellas Pharma (Netherlands) |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Stefan de Vogel |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Pharmacovigilance, Astellas Pharma Europe B.V, Leiden, The Netherlands |
| authorships[16].author.id | https://openalex.org/A5002078534 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-8020-3144 |
| authorships[16].author.display_name | John D. Seeger |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I25026578, https://openalex.org/I4210124242 |
| authorships[16].affiliations[0].raw_affiliation_string | Optum Epidemiology, Boston, MA, USA |
| authorships[16].institutions[0].id | https://openalex.org/I25026578 |
| authorships[16].institutions[0].ror | https://ror.org/02t110213 |
| authorships[16].institutions[0].type | education |
| authorships[16].institutions[0].lineage | https://openalex.org/I25026578 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | New England College of Optometry |
| authorships[16].institutions[1].id | https://openalex.org/I4210124242 |
| authorships[16].institutions[1].ror | https://ror.org/0370sjj75 |
| authorships[16].institutions[1].type | company |
| authorships[16].institutions[1].lineage | https://openalex.org/I4210124242 |
| authorships[16].institutions[1].country_code | US |
| authorships[16].institutions[1].display_name | Optum (United States) |
| authorships[16].author_position | last |
| authorships[16].raw_author_name | John Seeger |
| authorships[16].is_corresponding | True |
| authorships[16].raw_affiliation_strings | Optum Epidemiology, Boston, MA, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1891035?needAccess=true |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10279 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2748 |
| primary_topic.subfield.display_name | Urology |
| primary_topic.display_name | Urinary Bladder and Prostate Research |
| related_works | https://openalex.org/W2322724630, https://openalex.org/W2890137344, https://openalex.org/W4246575271, https://openalex.org/W2095422200, https://openalex.org/W2239424396, https://openalex.org/W2006432065, https://openalex.org/W2271725949, https://openalex.org/W2743658275, https://openalex.org/W2003638941, https://openalex.org/W2750698829 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 1 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 2 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1080/03007995.2021.1891035 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S206643269 |
| best_oa_location.source.issn | 0300-7995, 1473-4877 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0300-7995 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Current Medical Research and Opinion |
| best_oa_location.source.host_organization | https://openalex.org/P4310320547 |
| best_oa_location.source.host_organization_name | Taylor & Francis |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320547 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1891035?needAccess=true |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Current Medical Research and Opinion |
| best_oa_location.landing_page_url | https://doi.org/10.1080/03007995.2021.1891035 |
| primary_location.id | doi:10.1080/03007995.2021.1891035 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S206643269 |
| primary_location.source.issn | 0300-7995, 1473-4877 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0300-7995 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Current Medical Research and Opinion |
| primary_location.source.host_organization | https://openalex.org/P4310320547 |
| primary_location.source.host_organization_name | Taylor & Francis |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320547 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1891035?needAccess=true |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Current Medical Research and Opinion |
| primary_location.landing_page_url | https://doi.org/10.1080/03007995.2021.1891035 |
| publication_date | 2021-02-19 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W1968860914, https://openalex.org/W2037706235, https://openalex.org/W1833989893, https://openalex.org/W2801558063, https://openalex.org/W2107806473, https://openalex.org/W2110991424, https://openalex.org/W2005256857, https://openalex.org/W2156905627, https://openalex.org/W1605716039, https://openalex.org/W2067945145, https://openalex.org/W2082897746, https://openalex.org/W4232249876, https://openalex.org/W2094791001, https://openalex.org/W2625051927, https://openalex.org/W2126049444, https://openalex.org/W2913163651, https://openalex.org/W2793910813, https://openalex.org/W2605319374, https://openalex.org/W2973181612, https://openalex.org/W2186190256, https://openalex.org/W2497404211, https://openalex.org/W3208310322, https://openalex.org/W2786108669, https://openalex.org/W2887125585 |
| referenced_works_count | 24 |
| abstract_inverted_index.EU | 22 |
| abstract_inverted_index.in | 16 |
| abstract_inverted_index.no | 3 |
| abstract_inverted_index.of | 10 |
| abstract_inverted_index.or | 19 |
| abstract_inverted_index.PAS | 23 |
| abstract_inverted_index.The | 0 |
| abstract_inverted_index.and | 8 |
| abstract_inverted_index.men | 18 |
| abstract_inverted_index.use | 7 |
| abstract_inverted_index.risk | 9 |
| abstract_inverted_index.with | 13 |
| abstract_inverted_index.either | 17 |
| abstract_inverted_index.women. | 20 |
| abstract_inverted_index.Number: | 25 |
| abstract_inverted_index.between | 5 |
| abstract_inverted_index.cancer, | 11 |
| abstract_inverted_index.results | 1 |
| abstract_inverted_index.suggest | 2 |
| abstract_inverted_index.Register | 24 |
| abstract_inverted_index.compared | 12 |
| abstract_inverted_index.mirabegron | 6 |
| abstract_inverted_index.EUPAS16088. | 26 |
| abstract_inverted_index.association | 4 |
| abstract_inverted_index.medications, | 15 |
| abstract_inverted_index.antimuscarinic | 14 |
| abstract_inverted_index.<b>Registration:</b> | 21 |
| cited_by_percentile_year.max | 96 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5002078534 |
| countries_distinct_count | 4 |
| institutions_distinct_count | 17 |
| corresponding_institution_ids | https://openalex.org/I25026578, https://openalex.org/I4210124242 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.71147087 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |